IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
| Revenue (TTM) | $17.31B |
| Gross Profit (TTM) | $5.72B |
| EBITDA | $3.12B |
| Operating Margin | 13.70% |
| Return on Equity | 21.40% |
| Return on Assets | 5.08% |
| Revenue/Share (TTM) | $103.50 |
| Book Value | $40.41 |
| Price-to-Book | 6.55 |
| Price-to-Sales (TTM) | 2.56 |
| EV/Revenue | 3.324 |
| EV/EBITDA | 16.19 |
| Quarterly Earnings Growth (YoY) | 8.80% |
| Quarterly Revenue Growth (YoY) | 8.00% |
| Shares Outstanding | $164.80M |
| Float | $156.45M |
| % Insiders | 1.08% |
| % Institutions | 102.97% |
Volatility is currently expanding
US government debt-to-GDP exceeds 120%, while annual interest payments now surpass the budget for national defense. Our three best-performing stocks this quarter were Meta, IQVIA and Shell. Our three largest detractors this quarter were Danone, Heidelberg and Samsung Electronics.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.
IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.
IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.
IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
IQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial Solutions delivered 8.6% revenue growth, with AI adoption and data assets driving margin expansion and cross-selling opportunities.
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IQV and any ticker you trade — then tracks every position and per-strategy win rate.
